European biotech: 10 startups to watch in 2024
This issue of our newsletter is supported by Lonza.
While the biotech market size in Europe is about half that of the U.S., it is still a major global sector.
In fact, the European market holds $246 billion potential, according to a report by Boston Consulting Group.
Furthermore, the European Commission’s Ursula von der Leyen recently pledged to put innovation “at the center of Europe’s economy”, increasing research spending to further drive this growth.
This week, we take a closer look at 10 European biotech companies likely to make a big splash in this burgeoning sector.
To find out more, read the full article: “Europe’s rising biotech stars: 10 startups to watch in 2024”
A MESSAGE FROM OUR SPONSOR LONZA
Creating next-generation GS-CHO expression solutions
Over the past 30 years, CHO biotherapeutic expression systems have improved, boosting titers and shortening timelines predominantly through process optimisation. This webinar highlights Lonza’s recent innovations, focusing on omics and genome engineering which have enabled the development of new expression tools such as the GS Effex® cell line for more effective monoclonal antibodies.
Want to advertise with us? Become our next sponsor.
Recommended by LinkedIn
🔥 More noteworthy articles from this week:
While the first GLP-1 drug was FDA-approved in 2004, this class of drugs has a long, little-known history dating back to the 1980s. In fact, Pfizer might have even missed an opportunity to set foot in the GLP-1 market because of a decision it made back in the ’90s. In this article we delve into the details of this story.
Radiopharmaceuticals are a rapidly evolving class of drugs that combine radioactive isotopes with biological molecules to target and treat specific diseases, most notably in oncology and neurology. These agents have a dual role: as diagnostic tools, they help locate and visualize tumors or diseased tissue, while as therapeutic agents, they deliver targeted radiation to destroy those same cells.
The biotech market is still going strong as more startups focused on therapeutic research crop up. Just this week, Italian startup Aptadir Therapeutics launched with $1.6 million to bring a new class of investigational drugs to the clinic, as it focuses on correcting a chemical process known as DNA methylation to treat diseases that arise from its malfunction.
The recent uptick in the number of bird flu cases in the U.S. poses a threat to public health. The country’s health department has called on biotechs to develop vaccines to mitigate the outbreak. In this article, we have created a timeline of the latest advancements in bird flu vaccines, investments, and strategic partnerships aimed at addressing this pressing public health issue.
Despite its small population of fewer than 3 million people, Lithuania punches above its weight in the life sciences industry. Lithuania’s life sciences sector now boasts over 550 biotech companies, and the industry continues to expand. Though still emerging as a biotech startup hub, the country is already nurturing several promising ventures. Here, we take a look at six startups at the forefront of Lithuania’s growing biotech scene.
C4 Therapeutics (C4T) is a leader in the targeted protein degradation (TPD) field, with two oncology drug candidates currently in clinical trials and collaborations with pharma companies like Merck, Biogen and Roche. C4T’s degrader medicines are designed to harness the body’s natural protein recycling system to rapidly degrade disease-causing proteins. Our guest on this episode of the podcast is C4T’s CEO and president, Andrew Hirsch.
Currently, subcutaneous delivery – via needle-based syringes or pens – is the common route of administration for GLP-1 receptor agonists. However, this route is associated with several drawbacks. Sublingual delivery could be a more patient friendly alternative: it is easy, fast, reliable and may even reduce a number of side effects.
💡Enjoying these articles? Never miss a single publication of Labiotech by becoming a part of our community! Click here to join our mailing list.